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Abstract
Background: Antiretroviral therapy significantly reduces HIV viral burden and prolongs life, but does not cure HIV
infection. The major scientific barrier to a cure is thought to be the persistence of the virus in cellular and/or
anatomical reservoirs.
Discussion: Most efforts to date, including pharmaco, immuno or gene therapy, have failed to cure patients, with
the notable exception of a stem cell transplant recipient commonly known as the Berlin patient. This case has
revived interest in the potential to cure HIV infection and has highlighted the need to resolve critical questions in
the basic, pre-clinical and clinical research spheres as they pertain specifically to efforts to eradicate HIV from the
body of an infected person (a sterilizing cure) or at least render the need for lifelong antiretroviral therapy obsolete
(functional cure). This paper describes ongoing debates in each of these research spheres as they were presented
and discussed at a satellite session that took place at the 6
th International AIDS Society Conference on HIV
Pathogenesis, Treatment and Prevention in Rome in July 2011.
Summary: The resolution of these debates may have important implications for the search for a cure, the most
efficient ways to identify and test promising interventions, and ultimately the availability of such a cure to diverse
groups of HIV patients around the world.
Background
Despite initial optimism concerning the curative poten-
tial of highly active antiretroviral therapy (HAART) when
it became available in the mid-1990s [1], subsequent
laboratory findings and clinical experience revealed that
HAART does not eradicate HIV infection. In well-
suppressed patients, virus can be recovered from resting
CD4+ T cells [2-4], even in patients who have been suc-
cessfully treated for seven years or more [5]. In addition,
withdrawal of HAART almost inevitably results in viral
recrudescence [6].
A cure for HIV may be envisioned in different ways. A
functional cure resembles disease remission, in which
virus persists, but infection does not progress after treat-
ment interruption [7], preliminary evidence for which has
been reported in the VISCONTI trial [8]. A sterilizing
cure requires the eradication of all HIV and latently
infected cells from the body of an infected person. The
main stumbling block to a cure is the ability of the virus to
persist in reservoirs that are not cleared by the host
immune response or antiretroviral treatment (ART).
The nature of these reservoirs of persistent viral infec-
tion is the subject of intense debate. Most agree that
some fraction of virus that remains during suppressive
treatment exists in a latent, transcriptionally silent state,
and that ART-resistant cellular reservoirs might persist
either in long-lived cells or by proliferation of infected
cells [9]. However, the degree to which reservoirs are also
maintained by ongoing viral replication despite HAART
remains hotly contested. The argument is not simply aca-
demic: a cure will clearly require the disruption of latent
infection, but, to the extent that it occurs, will also need
to address ongoing replication that is refractory to cur-
rent antiretroviral therapy.
These and other basic science questions could be
addressed in animal models, but the challenge here con-
cerns the lack of an animal model that recapitulates
every feature of HIV infection. Mouse models, which
have the advantage of relative affordability, may have uti-
lity in characterizing persistent viral reservoirs and/or
evaluating curative interventions [10], but it is possible
that the extensive genetic modifications required to ren-
der them susceptible to HIV infection may compromise
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primates have the advantage of being natural hosts of
SIV infection [11], yet elements of the various simian
viruses, the hosts, and the interaction between these, dif-
fer sufficiently from the human experience to raise ques-
tions concerning the applicability of results generated in
these animal models too.
Several strategies have garnered sufficient basic labora-
tory support to warrant testing in vivo. It is unclear
whether such tests should proceed directly in humans, a
potentially risky undertaking, but with scientifically valid
results, or in animal models in which safety and possibly
efficacy might be evaluated, but with results of unknown
generalizability. Safety is an important consideration in
the development of new interventions for all diseases,
but in the context of curing HIV infection, is addition-
ally complicated in the patient population for whom a
cure might (especially initially) be tested, namely those
whose infection is already well controlled by current
HAART.
Those strategies currently undergoing testing include a
range of pharmacological, immunological and gene thera-
peutic interventions. Each rests on very different pre-
mises of how a cure might best be achieved, for example,
by disrupting the chromatin environment in which latent
virus resides, by disrupting the immune environment
that contributes to the establishment and/or persistence
of reservoirs, or by depriving the virus of target cells [12].
The only precedent for routinely curing a chronic viral
infection is by pharmacotherapy in the setting of the
hepatitis C virus (HCV). On the other hand, the only
case of an apparent cure of HIV more closely resembles a
gene therapy approach [13]. It is not clear which is most
promising, although a cure for HIV might well require a
combination of approaches.
The presence or absence of ongoing viral replication,
the merits of testing interventions in animals first or pro-
ceeding straight to humans, and the likelihood of curing
HIV using pharmacotherapy versus gene therapy were
each debated in a satellite session at the 6
th International
AIDS Society Conference on HIV Pathogenesis, Treat-
m e n ta n dP r e v e n t i o nh e l di nR o m ei nJ u l y2 0 1 1 .
Approximately 150 audience members listened to and
were invited to participate in each of three debates. The
arguments and discussion that took place in each of
three debates at this satellite session are presented here.
These and other questions in each of the research
spheres (basic, pre-clinical and clinical) are important
ones to solve in the search for a cure for HIV. Bringing
an end to the international HIV/AIDS pandemic will
require novel interventions both to prevent new infec-
tions and to cure the more than 30 million people cur-
rently estimated to be living with HIV.
Discussion
Is there ongoing viral replication under HAART?
Since HAART was introduced in the mid-1990s, it has
increased the lifespan of patients dramatically [14]. In
more recent years, as the number of available drug classes,
as well as individual drug potency and tolerability, has
increased, many patients can expect to suppress viral load
below the limit of detection in clinical practice, currently
defined as 50 copies per milliliter of blood [15]. With very
few exceptions, however, patients who stop taking
HAART experience rapid viral rebound to levels compar-
able to the viral set point at the onset of infection [6].
Clearly, although nominally undetectable (but detectable
by ultrasensitive assays), the virus persists in reservoirs in
a form that is impervious to current antiretroviral therapy
[2-5].
There are a number of ways in which reservoirs of virus
might persist: in anatomical sanctuary sites where drug
penetration or potency is suboptimal; as integrated but
transcriptionally silent provirus, maintained in long-lived
cells or by homeostatic proliferation; or by low levels of
ongoing replication that are incompletely suppressed by
HAART [9]. The authors of a recent paper posit that
cell-to-cell spread may contribute to viral persistence
despite the presence of HAART [16]. The extent to
which each of these contributes to viral recrudescence is
currently unclear [9].
One test of ongoing viral replication is to intensify ART
regimens to determine whether viral load can be reduced
beyond what is achieved with standard suppressive regi-
mens. Several trials have been conducted in which sup-
pressive regimens were intensified with NNRTIs, PIs,
maraviroc or raltegravir [17-23]. In each case, there was
no decrease in viremia or in the size of the viral reser-
voirs, at least as measured in the blood. These data were
interpreted to indicate a lack of ongoing viral replication,
and the maintenance of reservoirs of virus in long-lived
cells.
Ongoing replication might also be evidenced by
genetic evolution. Because HIV is known to generate
mutations with each round of replication [24], studies
have compared the genomes of pre-therapy virus with
those present in plasma after years of therapy [25,26]. In
each case, there is little evidence of divergence during
therapy.
The argument was made during the debate that if
there were ongoing accumulation of genetic variation,
then one might expect to see divergent virus post-ther-
apy, with or without the development of drug resistance.
In fact, in some cases there is production of predomi-
nant plasma clones that do not differ significantly from
pre-therapy virus. These findings together suggest a lack
of ongoing viral replication and maintenance of virus in
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infected cells.
One criticism of evidence from both kinds of studies
concerns the sensitivities of the assays used to detect vir-
emia or viral sequence evolution. The possibility was
raised that ongoing replication or sequence divergence
may be occurring below the limits of detection by the
single copy assay (SCA) or viral sequencing assays.
Although SCA values are themselves generally low (1-3
copies/ml) during suppressive therapy, this amount of
virus translates into a substantial residual viral load in an
infected individual. If active cycles of replication take
place at extremely low levels relative to persistent vire-
mia, it may not be detectable by even the most sensitive
assays. In addition, the SCA is unable to differentiate
between replication competent versus incompetent virus.
I tw a ss u g g e s t e dt h a tt h eS C Am a yi nf a c tb eam e a s u r e
of general cell apoptosis because as cells die and release
their contents, viral RNA transcripts would be detected
with this assay [27]. However, if cell death were responsi-
ble for the RNA detected, one would expect HIV DNA to
be present as well, but HIV DNA is generally not present
in plasma [17,18].
Anatomical sanctuary sites as a source of viral rebound
were also briefly considered. Tissue levels of ART are con-
siderably lower, especially in the brain [28] and such tis-
sues as lymph nodes [29] than those in plasma. It is
possible, then, that patients might experience ongoing
viral replication in tissues even when it is not observed in
blood. Because of the difficulty of sampling brain tissue,
cerebrospinal fluid (CSF) is taken as a surrogate, and the
extent to which the presence of virus in CSF indicates
ongoing viral replication is not clear. One argument
against sanctuary sites as a location of ongoing replication
and source of viral rebound is the ability of regimens that
do not cross the blood-brain barrier very well to nonethe-
less suppress the virus below the limit of detection [30].
A recent study has provided intriguing evidence that
there may be ongoing viral replication in at least a sub-
stantial fraction of patients. In the largest and longest
treatment intensification study to date, about one-third of
69 well-suppressed patients whose HAART regimen was
intensified by raltegravir experienced a transient increase
in 2-LTR circle frequency after approximately two weeks
[19]. Because raltegravir blocks the integration of reverse-
transcribed virus, it is difficult to imagine how the accu-
mulation of such episomes could occur in the absence of
de novo infection events.
Several issues were raised in response to this study: it is
not clear why only about one-third of patients experi-
enced this increase in episomes; it is not clear why the
times at which their levels peaked differed between
patients (ranging from 0 to 12 weeks during intensifica-
tion); and it is not clear what the half-life, sequence
diversity and replication competence of these 2-LTR cir-
cles is. The counter-argument was that the half-life is not
relevant in this context because what was measured was
an increase in 2-LTR circles over baseline and not their
decay. A subsequent analysis of episomal and proviral
reverse transcriptase sequences found in the peripheral
blood mononuclear cells of these patients revealed statis-
tically significant compartmentalization between these
two forms of DNA and the emergence of distinct genetic
populations at different time points, together suggesting
that episomal and proviral DNA may originate from dif-
ferent anatomical compartments and that there may be
stochastic release of virus from reservoirs with variable
pharmacological accessibility [31].
A member of the audience introduced another line
of evidence, which has since been published, suggest-
ing ongoing replication, namely the raised levels of
immune activation consistently observed even in well-
suppressed patients. In the context of the large ralte-
gravir intensification study [19], there was a decrease
in the activation of CD8+ T cells during intensification
that increased again when raltegravir was withdrawn
[32]. This finding is consistent with the observation in
one study of a trend towards a decrease in unspliced
HIV RNA and increased CD8+ T cell activation in the
ileum in five of seven patients undergoing maraviroc
intensification [20].
Much of the research that has been conducted in this
arena is in blood, largely because of the ease with which
it can be sampled. There was agreement that viral repli-
cation and persistence in tissues may differ significantly
from what can be observed in blood, and that one of
the difficulties in looking in tissues is knowing what to
divide by (as opposed to volume for blood), whether
that be total cell number, CD4+ T cell number, CCR5
RNA or some other measure. A member of the audience
contributed to this debate by describing ongoing unpub-
lished work in her laboratory concerning a comparison
of single proviral sequences in bone marrow, gut and
peripheral blood. For patients treated either during
acute or chronic infection, there is no viral sequence
evolution and for each patient virus in the plasma is
identical to sequences in cells both pre- and post-ther-
apy (Sarah Palmer, personal communication).
Knowing the determinants of persistent viremia will
likely inform what needs to be done to cure people. The
debate concluded with a concession that it is difficult to
prove a negative, the absence of ongoing viral replica-
tion, and that better assays - more sensitive and well
validated - as well as more extensive studies in tissues,
are needed before the question of ongoing viral replica-
tion can be resolved to universal satisfaction.
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animal models before human testing?
In most cases, regulatory agencies in the United States
and Europe require the testing of new medical interven-
tions (drugs, devices, biologics, vaccines, etc.) in animals
before progressing to human testing [33,34]. These are
intended to ensure safety and to provide some prelimin-
ary support for efficacy that justifies putting humans at
potential risk. However, animal studies can provide such
support only to the extent that they are generalizable to
humans.
The similarities between HIV and pathogenic SIV
infection in macaques are extensive. Both are character-
ized by chronic progressive infection associated with
opportunistic infections and central nervous system dis-
ease. In both, there are also instances of relatively benign
cases associated with low viremia and specific MHC-I
alleles. Similar kinetics of viremia are found for both HIV
and SIV, characterized by a peak during acute infection
followed by a dramatic decline. Furthermore, both viral
infections result in vigorous, but ultimately ineffective
immune responses. Key pathogenic events, such as
inflammation and chronic immune activation, mucosal
immune dysfunction, microbial translocation and high
levels of infection of CD4+ central memory T cells, are
present in both. In addition, in both cases viral replica-
tion can be suppressed by ART [11]. On this last point,
however, there is a difference that is critical in the con-
text of cure research, namely that primates often fail to
reach maximal viral suppression with the current ART
optimized for primates [35,36].
Differences such as this and others that may not yet be
fully characterized can have serious consequences, as
raised by the debate’s moderator, who cited the case of
TGN1412, a monoclonal antibody intended for the treat-
ment of leukemia and arthritis. During pre-clinical eva-
luation in macaques, no safety concerns were noted, but
clinical testing resulted in serious adverse effects [37]. It
was conceded that primate models may not always per-
fectly anticipate outcomes in humans, but that the
answer was to find better macaque models or to design
experiments that are more appropriate for existing mod-
els rather than to eliminate the non-human primate
(NHP) model altogether.
Despite occasional setbacks, much has been learned
about AIDS in NHP studies, including the early events of
virus transmission and dissemination; basic pathogenic
events in tissues; and the role of the host immune
response and other elements of pathogenesis using tech-
niques that would not be possible in humans, such as cell
depletion studies, repeated tissue sampling, and elective
necropsy [11]. As a counter-argument, the case was
made that virological assays for evaluating HIV reservoirs
before and following therapeutic intervention have been
established in humans and that much has been learned
from ex vivo and in vitro studies humans.
Furthermore, the only reported cure of infection has
o c c u r r e di nah u m a n[ 1 3 ] ,a n do t h e rs t u d i e si n v o l v i n g
gene therapy and pharmacotherapy are already ongoing in
humans [12]. Agents already approved to treat other con-
ditions, such as autoimmune disease, transplantation and
cancer, could be adapted for cure studies in HIV-positive
subjects in attempts to reduce immune activation and
inflammation or to reverse proviral latency. However, risk-
ier interventions, such as those involving stem cells, would
benefit from pre-clinical testing in NHP. In addition, mov-
ing some of the therapies currently being employed in
cancer patients with limited prognosis into HIV-positive
patients who are well suppressed and generally healthy
requires close consideration of the risk-benefit ratio and
poses ethical challenges that are not yet resolved [38].
One of the challenges in conducting NHP studies is the
lack of standardization or universally applicable model.
According to the research questions being posed,
researchers must use different species, virus, route and
dose of inoculation, treatment regimens, assays and
methods, such as sample collection. For example, study-
ing the effects of zinc finger nuclease-mediated CCR5
knockout requires the use of a R5-tropic SHIV. The use
of a virus with a mac239 envelope that is known to use
two or three other co-receptors would result in an unin-
terpretable study. While the selection of the appropriate
primate model requires careful consideration, there are
several models, each with its own set of characteristics,
offering the potential to find a model that is applicable to
the research question of interest [11,39]. In any type of
study designed to test a curative intervention, controlling
such parameters as duration of infection and ART regi-
men is much easier in NHPs than humans.
Finally, due largely to cost, there are small numbers of
animals for most NHP studies, making interpretation and
reaching statistical significance difficult. A member of the
panel asked for clarification of the costs of NHP studies
by stating, for the sake of comparison, that even a very
intensive 24-week human study, with multiple tissue
biopsies, including even apheresis, would cost $15,000-
$20,000 per subject, including the cost of the drug being
tested (Steven Deeks, personal communication). It was
conceded that NHP studies cost considerably more, at
least $20,000-$30,000 per animal.
A member of the audience raised a possibly less costly
alternative to humans or NHPs, namely humanized mice.
He claimed that all of the interventions used in humans
can be used and that because human cells are present,
standard immunological measures could be used (Victor
García, personal communication). It was agreed that
humanized mice have some interesting features that are
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but not necessarily as an alternative to NHPs.
Is an HIV cure more likely to consist of pharmacotherapy
or gene therapy?
The only precedent for routinely curing a chronic viral
infection is by pharmacotherapy in the setting of HCV.
On the other hand, the only case of an apparent cure of
HIV more closely resembles a gene therapy approach [13].
Clinical trials are currently ongoing, testing each of these
approaches, as well as immunotherapy [12].
There was disagreement about whether HIV is a genetic
disease and whether gene therapy is therefore suitable as a
curative strategy. Whether one of the main co-receptors
for HIV that permits infection to take place, namely
CCR5, or the integrated virus itself is considered, it was
argued that HIV can be thought of as a genetic disease.
Consistent with this philosophy, the argument was made
that the Berlin patient had a genotype (heterozygous for
the CCR5 dela-32 mutation) that permitted HIV infection
and was cured because of a bone marrow transplant from
a donor homozygous for that mutation.
Although curing viral infections is not commonplace,
current medical treatment is dominated by pharmacother-
apy and, as such, much is known about its testing and
implementation. In fact, several pharmacotherapeutic
interventions, including drugs that activate latent HIV
(including histone deacetylase (HDAC) or methylation
inhibitors, cytokines and disulfiram) or immune modula-
tors (antibiotic, anti-rheumatologic, anti-PD-1 and protein
kinase C (PKC) modulators), show promise in in vitro or
animal models of latency [40], and are in clinical develop-
ment for the treatment of non-HIV conditions [12]. The
advantage of pursuing these pharmacotherapeutic strate-
gies is that their safety profile is fairly well understood and
they have the potential to proceed rapidly from bench to
bedside.
On the other hand, trials of gene therapy are ongoing,
using zinc finger nucleases (ZFNs) to excise CCR5 from
CD4+ T cells ex vivo [12]. To date, no safety signals have
been noted in these trials in which genetically modified
autologous cells are reinfused into patients [41,42]. Safety
is a key concern for gene therapy, with a history of signif-
icant toxicity and even mortality in the setting of other
diseases [43]. Notably, much is already known about the
apparent safety of deleting CCR5 because of the existence
of a small group of people with a mutation consisting of a
32-bp deletion that leaves them without a functional
CCR5 protein [44]. Still, pharmacotherapy-induced toxi-
cities are easier to reverse than those resulting from gene
therapy.
Balancing safety and potency has been difficult to date,
especially with pharmacotherapeutic agents designed to
reverse transcriptional latency [40]. One solution would
be to combine several agents either within or between
classes of mode of action. For example, multiple HDAC
inhibitors, or combinations of HDAC inhibitors with
immune modulation and possibly even ART intensifica-
tion will quite possibly be more effective than any single
agent alone. Similarly, there are several different gene
therapy strategies currently under investigation that
might lend themselves to combination. These include:
the choice of target cells, such as T cells versus stem
cells (the latter of which could then replenish all
lineages of the hematopoietic system); the choice of
technology, for example, targeting enzymes or siRNA;
and the choice of target genetic material, such as CCR5
or the integrated virus itself [45].
Specificity is also a difficulty faced in very different ways
by both pharmacotherapy and gene therapy. Without a
means of identifying and therefore specifically targeting
only latently infected cells, it is difficult to envision how
pharmacotherapy would not affect bystander cells in
potentially deleterious ways. Additionally, therapies
designed to modify epigenetic processes will a priori affect
cellular genes in unintended and potentially harmful ways.
These side effects may be transient or reversible, but possi-
bly at the cost of efficacy. Gene therapy is a way to target
very specific processes or elements that are essential to the
viral life cycle, but is only as specific as the technology in
question.
There is evidence that ZFNs designed to target CCR5
may not be 100% specific to the intended DNA sequence
[46], and the safety consequences of cleaving unintended
targets are unknown and very possibly serious. On the
other hand, because a homing endonuclease recognizes a
22 bp sequence, the likelihood of that recognition site
occurring by random chance is orders of magnitude less
than the number of nucleotides occurring in the human
genome, suggesting that these enzymes at least have the
requisite specificity. Another potential challenge for gene
therapy relates to the relatively low rate of cell transfor-
mation, and for both gene therapy and some types of
pharmacotherapy, such as HDAC inhibitors or PKC
modulators, there is a risk of the development of cancer.
It currently seems that pharmacotherapy would be more
scalable, deliverable and cost effective than gene therapy,
especially because the majority of HIV-infected individuals
live in regions of the world where the delivery of even cur-
rently available ART presents a daunting challenge. How-
ever, if gene therapy provided a reliable cure, then scalable
delivery options may well be developed.
Summary
Optimism regarding the potential to cure HIV infection
has waxed and waned during the course of the epi-
demic. Several factors have contributed to the recently
renewed enthusiasm regarding the possibility of a cure
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mechanisms of viral persistence; a growing array of ther-
apeutic tools with the potential to cure HIV; targeted
research funding directed to the search for a functional
or sterilizing cure; and, not least, the first documented
case of a cure of HIV infection in the Berlin patient
[13], as well as preliminary evidence of a functional cure
in patients who initiated ART early in infection and
maintained control of infection several years after treat-
ment discontinuation [8].
Although much has been learned concerning the
mechanisms whereby virus persists in the face of HAART
and a vigorous immune response, and there is general
agreement about several of these mechanisms, one issue
awaiting resolution is the extent to which there is ongoing
viral replication [9]. This is an important issue that may
shape cure strategies, especially those based on reactivat-
ing the expression of latent viral infection.
Animal models have so far been relatively under-utilized
in the search for a cure, in part because of the lack of
clarity regarding the applicability of the available models.
Further research will likely shed light on those elements of
mouse and NHP models that need optimization, although
one ongoing challenge is the high cost associated with the
use of NHP. As in other areas of biomedical research
though, animal models provide the opportunity to address
questions that would not be possible in humans.
Several concepts are already in clinical trials and are pre-
dicated on different concepts of how a cure might best be
achieved. These encompass pharmacotherapy, gene ther-
apy and immunotherapy [12]. Each has significant advan-
tages and potential drawbacks in terms of safety,
specificity and acceptability. Although pharmacotherapy is
currently easier to envision as an affordable and more
widely deliverable solution, advances in gene therapy are
progressing rapidly and there is intense interest in simpli-
fying its execution and delivery.
While not the explicit topic of any of the debates in this
session, it is clear that several ethical issues also require
resolution, such as the level of risk that is acceptable for a
curative intervention in patients who are otherwise rela-
tively healthy and well suppressed on HAART [38], as well
as the deliverability of a cure to those who need it, most of
whom live in resource-poor settings. However, given the
enormous challenge of providing lifelong HAART to the
more than 30 million people currently living with HIV
[47], a cure will provide an important contribution to the
goal of ending the international HIV/AIDS pandemic.
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